Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARION phase II trial of durvalumab with chemoradiotherapy for unresectable localized oesophageal cancer
2018-000708-40Phase 2Active
- Sponsor
- Unicancer
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in esophageal cancer (2 arms), sponsored by Unicancer. Primary endpoints: Centrally reviewed progression-free survival and Local progression-free survival. Started Oct 2018; status: active.
02
Drugs
durvalumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on 2018-000708-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000708-40.